Photochemical decontamination treatment of whole blood or blood components
AssigneeDiamond Scientific Co.
InventorsGary P. Wiesehahn, Richard P. Creagan
Life of this patent
Estimating the term…
Abstract
Biological compositions are decontaminated by treatment with furocoumarin derivatives and irradiation under particular conditions in which the proteins retain their original physiological activities and any pathogenic microorganisms and polynucleotide fragments thereof are rendered inactive. It has been found that reduction of the amount of dissolved oxygen in the treatment solution substantially inhibits denaturation of the proteins.
Claims22
A method for decontaminating a blood clotting factor containing composition of viral contaminants, in a manner which substantially maintains the biological activity of the blood clotting factors, said method comprising adding to the blood clotting factor containing composition at least one furocoumarin, and irradiating the furocoumarin containing composition under U-V light, wherein the amount of furocoumarin and irradiation conditions are sufficient to inactivate substantially all the viral contaminants, and wherein the concentration of dissolved oxygen is reduced to a level sufficient to substantially inhibit the denaturation of the blood clotting factors.
A method for decontaminating a blood clotting factor containing composition of viral contaminants in a manner which substantially maintains the biological activity of the blood clotting factors, said method comprising adding to the blood clotting factor containing composition at least one furocoumarin such that the total furocoumarin concentration is at least 1 .mu.g/ml and not more than 300 .mu.g/ml, and irradiating the furocoumarin containing composition under U-V light which wavelengths are in the range of about 300 nm to 400 nm and at an intensity of about 0.1 mw/cm.sup.2 to 5 w/cm.sup.2 and at a depth of at least 0.025 millimeters for a total irradiation time of about 5 minutes to about 12 hours, and wherein the level of dissolved oxygen in the blood clotting factor containing composition is substantially reduced to substantially inhibit the denaturation of the blood clotting factors.
Dependencies are inferred from the claim text.